Trial reportAnnals of the rheumatic diseases2007
Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide.
Trial report in Annals of the rheumatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Guideline
- The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Pooled it
- Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis.Arthritis care & research · 2010Pooled it
- Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial.Clinical journal of the American Society of Nephrology : CJASN · 2010Trial
- Granulomatosis with polyangiitis with rapidly progressive glomerulonephritis treated with a multipronged approach-a case based review.CEN case reports · 2025Review
- Review
- New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis.Frontiers in immunology · 2021Review
- The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis.World journal of nephrology · 2019Review
- [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].Zeitschrift fur Rheumatologie · 2017Review
- Article
- Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients.Rheumatology international · 2016Observational
- Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.Journal of the American Society of Nephrology : JASN · 2015Review
- Concurrent pulmonary hemorrhage and deep vein thrombosis in a child with ANCA-associated vasculitis: case report and review of literature.Pediatric rheumatology online journal · 2015Review
- Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease.Clinical kidney journal · 2014Article
- Treatment of ANCA-associated vasculitis, where to go?Clinical reviews in allergy & immunology · 2012Review
- Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis.Kidney international supplements · 2012Article
- Progress in treatment of ANCA-associated vasculitis.Arthritis research & therapy · 2012Review
- ANCA-associated small vessel vasculitis: clinical and therapeutic advances.Current rheumatology reports · 2010Review
- ANCA negative pauci-immune glomerulonephritis with systemic involvement.Indian journal of nephrology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActive anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is commonly treated with cyclophosphamide, a drug with serious side effects, and with corticosteroids.
objectiveTo determine the efficacy of a possible alternative drug for cyclophosphamide, oral mycophenolate mofetil (MMF) 1000 mg twice daily and oral prednisolone 1 mg/kg once daily as remission induction treatment.
methods32 consecutive patients with 34 episodes of active vasculitis who could not be treated with cyclophosphamide were diagnosed for a median (range) of 6.0 (0.3-22) years and experienced 4 (0-14) relapses prior to the current episode. Treatment response and relapse-free survival were analysed.
resultsComplete remission (CR) was obtained in 25 (78%) patients, partial remission (PR) in 6 (19%), whereas 1 (3%) patient did not respond. 19 patients relapsed, 13 (52%) after CR, 14 (3-58) months after starting the treatment and 6 (100%) after PR, 6 (2-10) months after starting the treatment. The median relapse-free survival was 16 months, comparable with the interval between the previous relapse and the current MMF-treated relapse (17 (3-134) months). Relapse-free survival at 1, 3, and 5 years was 63%, 38% and 27%, respectively. Patients who had been treated successfully with cyclophosphamide before responded better (CR 84%, relapse 50%) than those who had not (CR 50%, relapse 100%). Minor gastrointestinal side effects and infections occurred frequently. MMF was prematurely discontinued due to adverse effects in two patients.
conclusionMMF, in combination with prednisolone, can induce remission in patients with relapses of AAV intolerant to cyclophosphamide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.